Abstract

Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P

Original languageEnglish (US)
Pages (from-to)464-471
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume1
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Homocysteine
Alzheimer Disease
Cardiovascular Diseases
Logistic Models
Odds Ratio
Confidence Intervals
Inflammation
Brain
Research

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Dementia
  • Homocysteine
  • Lp-PLA2

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. / Texas Alzheimer's Disease Research and Care Consortium.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 1, No. 4, 01.12.2015, p. 464-471.

Research output: Contribution to journalArticle

Texas Alzheimer's Disease Research and Care Consortium. / Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2015 ; Vol. 1, No. 4. pp. 464-471.
@article{6472b86eed804703b0dcc0ed9a78fca1,
title = "Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease",
abstract = "Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95{\%} confidence interval [CI] = 1.22-2.97; P",
keywords = "Alzheimer's disease, Biomarkers, Dementia, Homocysteine, Lp-PLA2",
author = "{Texas Alzheimer's Disease Research and Care Consortium} and Doody, {Rachelle S.} and Jasenka Demirovic and Ballantyne, {Christie M.} and Wenyaw Chan and Robert Barber and Suzanne Powell and Valory Pavlik and Rachelle Doody and Susan Rountree and Paul Massman and Eveleen Darby and Tracy Evans and Aisha Khaleeq and Gregory Schrimsher and Andrew Dentino and Ronnie Orozco and Thomas Fairchild and Janice Knebl and O'Bryant, {Sid E.} and Hall, {James R.} and Barber, {Robert C.} and Douglas Mains and Lisa Alvarez and Erin Braddock and Rosemary McCallum and Leigh Johnson and Perrie Adams and Roger Rosenberg and Myron Weiner and Benjamin Williams and Mary Quiceno and Joan Reisch and Ryan Huebinger and Guanghua Xiao and Doris Svetlik and Amy Werry and Janet Smith and Donald Royall and Raymond Palmer and Marsha Polk",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.dadm.2015.08.001",
language = "English (US)",
volume = "1",
pages = "464--471",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease

AU - Texas Alzheimer's Disease Research and Care Consortium

AU - Doody, Rachelle S.

AU - Demirovic, Jasenka

AU - Ballantyne, Christie M.

AU - Chan, Wenyaw

AU - Barber, Robert

AU - Powell, Suzanne

AU - Pavlik, Valory

AU - Doody, Rachelle

AU - Rountree, Susan

AU - Massman, Paul

AU - Darby, Eveleen

AU - Evans, Tracy

AU - Khaleeq, Aisha

AU - Schrimsher, Gregory

AU - Dentino, Andrew

AU - Orozco, Ronnie

AU - Fairchild, Thomas

AU - Knebl, Janice

AU - O'Bryant, Sid E.

AU - Hall, James R.

AU - Barber, Robert C.

AU - Mains, Douglas

AU - Alvarez, Lisa

AU - Braddock, Erin

AU - McCallum, Rosemary

AU - Johnson, Leigh

AU - Adams, Perrie

AU - Rosenberg, Roger

AU - Weiner, Myron

AU - Williams, Benjamin

AU - Quiceno, Mary

AU - Reisch, Joan

AU - Huebinger, Ryan

AU - Xiao, Guanghua

AU - Svetlik, Doris

AU - Werry, Amy

AU - Smith, Janet

AU - Royall, Donald

AU - Palmer, Raymond

AU - Polk, Marsha

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P

AB - Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) have been linked to inflammation and Alzheimer's disease (AD). Using a case-control design, we examined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on AD risk. Methods: AD cases and controls were from the Texas Alzheimer's Research and Care Consortium study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We assayed for Lp-PLA2 in the brain tissue of cases and controls. Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.22-2.97; P

KW - Alzheimer's disease

KW - Biomarkers

KW - Dementia

KW - Homocysteine

KW - Lp-PLA2

UR - http://www.scopus.com/inward/record.url?scp=84949563915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949563915&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.08.001

DO - 10.1016/j.dadm.2015.08.001

M3 - Article

C2 - 27239525

AN - SCOPUS:84949563915

VL - 1

SP - 464

EP - 471

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

IS - 4

ER -